Furthermore, Zhou et al. have shown that tumor-intrinsic TIGIT can substantially inhibit NK-cells and CD8+ T-cells-mediated anti-tumoral immune responses and pave the way for tumor growth in vivo [35]. This evidence concerns the gene CD8A and neoplasm.